Загрузка страницы
Все видеоНовые видеоПопулярные видеоКатегории видео

Follicular Lymphoma: Changes in the Treatment Landscape

Experts Bruce Cheson, MD; Nathan Fowler, MD; and Anas Younes, MD, discuss the most recent challenges and advancements in Follicular Lymphoma, including the FDA’s recent approvals of subcutaneously administered rituximab and copanlisib.

Видео Follicular Lymphoma: Changes in the Treatment Landscape канала OncLive
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
13 октября 2017 г. 1:22:49
00:58:11
OncLive
Теги
Правообладателям
Жалоба
Комментарии
Другие видео канала
Clinical Development of Cetuximab in Metastatic Colorectal CancerClinical Development of Cetuximab in Metastatic Colorectal CancerPathologic Classification of Neuroendocrine TumorsPathologic Classification of Neuroendocrine TumorsManaging Ibrutinib Toxicity in CLLManaging Ibrutinib Toxicity in CLLMSI Status and Immunotherapy in Advanced Colorectal CancerMSI Status and Immunotherapy in Advanced Colorectal CancerHER2-Targeted Therapy in Early Stage HER2+ Breast CancerHER2-Targeted Therapy in Early Stage HER2+ Breast CancerSuspecting Polycythemia Vera: Challenges in DiagnosisSuspecting Polycythemia Vera: Challenges in DiagnosisMDS: Understanding Disease Characteristics and ProgressionMDS: Understanding Disease Characteristics and ProgressionCALGB 80405 Trial Results in Metastatic Colorectal CancerCALGB 80405 Trial Results in Metastatic Colorectal CancerBiosimilar TrastuzumabBiosimilar TrastuzumabImmunotherapy for Brain MetastasesImmunotherapy for Brain MetastasesFuture Therapies in Multiple Myeloma TreatmentFuture Therapies in Multiple Myeloma TreatmentMaintenance Therapy for AMLMaintenance Therapy for AMLCLEOPATRA: Treating HER2-Positive Breast CancerCLEOPATRA: Treating HER2-Positive Breast CancerRole of Phlebotomy in Polycythemia VeraRole of Phlebotomy in Polycythemia VeraImmunotherapy: Toxicity, Pseudo-Progression, and Varied ResponsesImmunotherapy: Toxicity, Pseudo-Progression, and Varied ResponsesPractical Considerations for Using Lenvatinib in HCCPractical Considerations for Using Lenvatinib in HCCRelapse After CML Treatment DiscontinuationRelapse After CML Treatment DiscontinuationDifferences Among PARP Inhibitors in Ovarian CancerDifferences Among PARP Inhibitors in Ovarian CancerIpilimumab Side Effect Management in MelanomaIpilimumab Side Effect Management in MelanomaSchedules for Gemcitabine, Nab-Paclitaxel for Pancreatic CancerSchedules for Gemcitabine, Nab-Paclitaxel for Pancreatic CancerCombination Immunotherapy Treatment DurationCombination Immunotherapy Treatment Duration
Статистика портала
Яндекс.Метрика
© 2008-2024 «Информационно-развлекательный портал города Верхняя Салда»
| Карта портала | Реклама | Контакты | Сообщить об ошибке | Соглашения
salda.ws salda.ws@mail.ru
Сейчас на сайте: 512 Статистика портала